XenoTech

07/15/2023

Looking for new and scientific content and news from XenoTech? Then head over to BioIVT for valuable updates on research as well as normal and disease-state and related test systems for a variety of additional applications: https://www.linkedin.com/company/bioivt/

07/13/2023

Drug-induced liver injury (DILI) is the leading cause of acute liver failure and a major reason for liver transplantation. One of the most prominent forms of clinically observed DILI is cholestatic DILI. Cholestasis is characterized by impaired hepatic bile flow and may be induced by several different mechanisms. Cholestatic DILI can occur as the sole DILI phenotype or as a comorbidity with other DILI phenotypes. This from BioIVT looks at the effect of drugs that cause cholestatic DILI on bile acid transport and metabolism:https://assets.ctfassets.net/wirgejq7s9c7/41QTGN69yiDpteKZIzzvFV/a8e6cb6792c61eed25b324734ad27f84/ISSX_2022_Poster_Kralj_final.pdf

07/11/2023

Do you have questions about our new tiered study design options? Join Dr. Joanna Barbara, Kansas City Site Lead for BioIVT’s ADME Research Services and Products, for a live webinar presentation followed by Q&A on July 27th at 11am ET to learn more about how the new tiers work, the benefits of each tier, and how to decide which tier is right for you: https://hubs.ly/Q01XhVVC0

07/10/2023

"When should I be planning my / / drug- studies?" We've got some answers-- read our blog post discussing strategic timing of studies to set your drug compound up for success: https://bioivt.com/blogs/timing-of-in-vitro-studies-early-thorough-adme-for-your-compounds-success?utm_source=XTsocial&utm_medium=XTsocial&utm_campaign=XTFacebook&utm_id=XTFacebook&utm_term=ADMETiming

07/07/2023

The unbound intracellular concentration (ICC) is the driving force for processes that occur inside , including , induction and inhibition (metabolic and ), efflux-based , and . The absence (or reduction) of any of these processes can result in sub-optimal predictions of effects. Model selection is critical for accurate prediction of in vivo effects. Learn more in this from BioIVT:https://assets.ctfassets.net/wirgejq7s9c7/1ocB8XFw54QXzIkG3t3hWr/73db1f760268d875d2344fa9259108a2/IMPROVING_IN_VIVO_PREDICTIONS_FROM_IN_VITRO_HEPATOCYTE_MODELS_MODEL_SELECTION__PROTEIN_EFFECTS__AND_TRANSPORTER_REGULATION.pdf

07/06/2023

We’re looking forward to presenting a on “Antibody drug conjugates (ADCs): In Vitro Evaluation of Potential” at next week’s Gordon Research Conference on progressing (https://www.grc.org/drug-metabolism-conference/2023/). Request a meeting with Dr. Limaye if you’ll be attending or would like to discuss: https://hubs.ly/Q01WwM5R0 and make sure to follow BioIVT to access the poster once it’s available: https://www.linkedin.com/company/bioivt/

Abstract: Antibody drug conjugates (ADCs) are a novel modality leveraging monoclonal antibody (mAb)-mediated delivery of a cytotoxic payload molecule to its target. The small molecule conjugated to mAb can be released in unconjugated form and contribute to the drug-drug interaction (DDI) potential, therefore, both the antibody and the small molecule drug component should be considered. Here we present the summary and outcome of in vitro DDI studies conducted for several ADC programs at our facility. These studies included metabolic stability, metabolite identification, reaction phenotyping of CYPs and UGTs, CYP inhibition and induction potential, UGT inhibition potential, and potential as a substrate or inhibitor of transporters…

07/05/2023

Next week we’ll send our first news and resources update through BioIVT’s email system and switch to posting through BioIVT’s social media. Make sure you’ve resubscribed (https://hubs.ly/Q01SQsQj0) and follow BioIVT (https://www.linkedin.com/company/bioivt/) so you don’t miss out.

07/03/2023

Dir. of Consulting, Dr. Pallavi Limaye, recently detailed and drug- studies geared towards a audience in a post covering:
- Objectives of standard DDI studies in
- Considerations in design
- Strategic timing (& more!)
Read the overview here: https://bioivt.com/blogs/adme-and-drug-drug-interactions-for-the-toxicologist?utm_source=XTsocial&utm_medium=XTsocial&utm_campaign=XTFacebook&utm_id=XTFacebook&utm_term=ADME4Tox and download the slides here:https://assets.ctfassets.net/wirgejq7s9c7/71F1bvZI5romvnKd4r9zyv/1fbb64661d99f75768c625b96f29312e/BioIVT_In_Vitro_Drug-Drug_Interaction__DDI__and_ADME_Considerations_for_Toxicologists_5.23.pdf

06/30/2023

Do you know which and drug- studies you actually need to perform? While there may not be an exact checklist, regulatory agencies have made some expectations clear... https://bioivt.com/blogs/what-in-vitro-metabolism-and-ddi-studies-do-i-actually-need?utm_source=XTsocial&utm_medium=XTsocial&utm_campaign=XTFacebook&utm_id=XTFacebook&utm_term=NeededStudies

06/29/2023

Did you miss our June Symposium? You can now access the recordings and slides for several of the presentations, including “Improving Predictions from Models: Model Selection, Protein Effects, and Regulation,” Potential of Major Pharmaceutical Excipients on Transporters and Enzymes” and “In Vitro Aspects of ICH M12, Industry and Technology” here:

Download a copy of BioIVT's presentations from the 2023 Advanced In Vitro ADME Strategies: ICH Guidelines & Novel Methodologies Symposium.

06/28/2023

With over 3500 respondents to our industry survey on when and why researchers are running various studies, including , and , 96% of respondents said they had experienced negative repercussions from postponing these studies.

Take a look at the survey results infographic to read about when most researchers are performing ADME/ & testing, see what the top 4 repercussions and risks are from postponing, and the top 3 benefits to running more testing during preclinical research: https://bioivt.com/resources/articles-publications?entry=vSvbCm8TSoCORIsRweJjT&utm_source=XTsocial&utm_medium=XTsocial&utm_campaign=XTFacebook&utm_id=XTFacebook&utm_term=IndustrySurvey

06/27/2023

Since many compounds bind to red blood cells, which are 99% of cellular space in blood, determining parameters by only measuring drug concentration in plasma can significantly impact clearance and cause inaccuracies in calculations. That’s why the majority of polled researchers said they regularly conduct red blood cell partitioning with plasma protein binding studies. Read more: https://bioivt.com/blogs/why-do-most-polled-researchers-run-red-blood-cell-partitioning-studies-with-plasma-protein-binding?utm_source=XTsocial&utm_medium=XTsocial&utm_campaign=XTFacebook&utm_id=XTFacebook&utm_term=RBCpoll

06/26/2023

We’ve officially switched to BioIVT’s email system, so now the countdown is on for XenoTech’s social media accounts. We’ll be making the switch on July 15th, so make sure you’ve followed by then to ensure you don’t miss any important , or research news:

BioIVT | 7,716 followers on LinkedIn. ELEVATING SCIENCE | BioIVT, formerly BioreclamationIVT, is a leading global provider of high-quality biological specimens and value-added services. We specialize in control and disease state samples including human and animal tissues, cell products, blood and ot...

06/24/2023

Time is running out! Our next newsletter, including links to the recordings from our June Symposium, information on our new & study tiers, and more is scheduled for early July. Make sure you’ve subscribed to receive emails from BioIVT in order to receive it!

06/22/2023

How does and of a compound fit into its development? In our How We Help series we’ve provided an overview of science and derisking strategies associated with using metabolism data to evaluate metabolite formation and risk of potential drug- later in : https://bioivt.com/blogs/what-is-dmpk-and-how-does-it-fit-into-drug-development?utm_source=XTsocial&utm_medium=XTsocial&utm_campaign=XTFacebook&utm_id=XTFacebook&utm_term=WhatIsDMPK

06/21/2023

Our most popular blog entry for 2022 was our infographic about how you can leverage your data to showcase your compound in ways that will maximize its value:

Since most new drugs fail because of ADME/Tox, you can add considerable value to your compound by conducting early testing and preemptively demonstrating low risk data.

/ and studies only cost a small fraction of the potential financial benefits that can be gained by providing this data. The data not only satisfies regulatory requirements and avoids the considerable expense of clinical failures, additional studies and approval delays, but also helps guide the development of the drug candidate and helps with ensuring patient safety.

View the infographic: https://bioivt.com/resources/articles-publications?entry=3TwJd0G2qKTmQ89GbzAHsC&utm_source=XTsocial&utm_medium=XTsocial&utm_campaign=XTFacebook&utm_id=XTFacebook&utm_term=DeriskInfographic

06/20/2023

We asked some of our experts to address frequently asked questions about enzyme induction studies and discuss recommendations to achieve successful regulatory submission. Take a look at their responses here: https://bioivt.com/blogs/in-vitro-induction-studies-elements-of-design-and-important-considerations-in-data-analysis?utm_source=XTsocial&utm_medium=XTsocial&utm_campaign=XTFacebook&utm_id=XTFacebook&utm_term=InductionOverview

06/19/2023

We’re happy to announce that we recently added a Waters Corporation Xevo G3 to our equipment lineup, the first to be installed in the region. It will be used for our ID studies, including incubations with BioIVT -fibroblast co-cultures for low turnover compounds. Learn more about this service: https://bioivt.com/in-vitro-metabolite-identification?utm_source=XTsocial&utm_medium=XTsocial&utm_campaign=XTFacebook&utm_id=XTFacebook&utm_term=NewAS